Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights

As of April 8, 2026, implicit 90% of covering analysts support their “Buy” ratings for Nuvation Bio Inc. (NYSE:NUVB), and the statement terms people of $12 implies an upside of 166.08%.

On April 2, 2026, Wedbush maintained its “Buy” standing and $11 terms target, providing a favorable backdrop arsenic Nuvation Bio Inc. (NYSE:NUVB) expanded its strategical scope the time before.

On April 1, 2026, Nuvation Bio Inc. (NYSE:NUVB) added Japan rights to its exclusive licence woody with Daiichi Sankyo. This would assistance the institution the sole close to make and marketplace safusidenib worldwide.

This improvement strengthens Nuvation Bio Inc. (NYSE:NUVB)’s capableness to enactment further work and regulatory improvement successful IDH1-mutant glioma by enabling the ongoing Phase 3 SIGMA survey to widen into Japan and providing entree to each existent and aboriginal data. As a attraction attraction for high-risk astrocytoma, safusidenib, an oral selective mutant IDH1 inhibitor, has demonstrated encouraging efficacy, including long-lasting responses and extended progression-free endurance successful Phase 1 and 2 trials.

Nuvation Bio Inc. (NYSE:NUVB) is simply a biopharmaceutical institution processing caller treatments for difficult-to-treat cancers. The institution was founded by David Hung successful 2018, and its office are successful New York City.

While we admit the imaginable of NUVB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.